Virios Therapeutics received a letter from Nasdaq stating that their common stock failed to comply with the minimum bid price requirement for continued listing, and they have requested a hearing to present a plan to regain compliance.
AI Assistant
DOGWOOD THERAPEUTICS INC
2024
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.